|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
McGoldrick CA, Jiang YL, Paromov V,
Brannon M, Krishnan K and Stone WL: Identification of oxidized
protein hydrolase as a potential prodrug target in prostate cancer.
BMC Cancer. 14:772014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Damber JE and Aus G: Prostate cancer.
Lancet. 371:1710–1721. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shavers VL, Underwood W and Moser RP:
Race/ethnicity and the perception of the risk of developing
prostate cancer. Am J Prev Med. 37:64–67. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ma S, Chan YP, Kwan PS, et al:
MicroRNA-616 induces androgen-independent growth of prostate cancer
cells by suppressing expression of tissue factor pathway inhibitor
TFPI-2. Cancer Res. 71:583–592. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Filipowicz W, Bhattacharyya SN and
Sonenberg N: Mechanisms of post-transcriptional regulation by
microRNAs: are the answers in sight? Nat Rev Genet. 9:102–114.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bartel DP: MicroRNAs: target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Esquela-Kerscher A and Slack FJ: Oncomirs
- microRNAs with a role in cancer. Nature Rev Cancer. 6:259–269.
2006. View
Article : Google Scholar
|
|
11
|
Lu J, Getz G, Miska EA, et al: MicroRNA
expression profiles classify human cancers. Nature. 435:834–838.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schaefer A, Stephan C, Busch J, Yousef GM
and Jung K: Diagnostic, prognostic and therapeutic implications of
microRNAs in urologic tumors. Nat Rev Urol. 7:286–297. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fendler A, Jung M, Stephan C, et al:
miRNAs can predict prostate cancer biochemical relapse and are
involved in tumor progression. Int J Oncol. 39:1183–1192.
2011.PubMed/NCBI
|
|
14
|
Schaefer A, Jung M, Kristiansen G, et al:
MicroRNAs and cancer: current state and future perspectives in
urologic oncology. Urol Oncol. 28:4–13. 2010. View Article : Google Scholar
|
|
15
|
Zhou Y, Wu D, Tao J, Qu P, Zhou Z and Hou
J: MicroRNA-133 inhibits cell proliferation, migration and invasion
by targeting epidermal growth factor receptor and its downstream
effector proteins in bladder cancer. Scand J Urol. 47:423–432.
2013. View Article : Google Scholar
|
|
16
|
Ventura A and Jacks T: MicroRNAs and
cancer: short RNAs go a long way. Cell. 136:586–591. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cui L, Zhou H, Zhao H, et al: MicroRNA-99a
induces G1-phase cell cycle arrest and suppresses tumorigenicity in
renal cell carcinoma. BMC Cancer. 12:5462012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sun D, Lee YS, Malhotra A, et al: miR-99
family of MicroRNAs suppresses the expression of prostate-specific
antigen and prostate cancer cell proliferation. Cancer Res.
71:1313–1324. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lerman G, Avivi C, Mardoukh C, et al:
MiRNA expression in psoriatic skin: reciprocal regulation of
hsa-miR-99a and IGF-1R. PloS One. 6:e209162011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sun J, Chen Z, Tan X, et al:
MicroRNA-99a/100 promotes apoptosis by targeting mTOR in human
esophageal squamous cell carcinoma. Med Oncol. 30:4112013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nagayama K, Kohno T, Sato M, Arai Y, Minna
JD and Yokota J: Homozygous deletion scanning of the lung cancer
genome at a 100-kb resolution. Genes Chromosomes Cancer.
46:1000–1010. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li XJ, Luo XQ, Han BW, Duan FT, Wei PP and
Chen YQ: MicroRNA-100/99a, deregulated in acute lymphoblastic
leukaemia, suppress proliferation and promote apoptosis by
regulating the FKBP51 and IGF1R/mTOR signalling pathways. Br J
Cancer. 109:2189–2198. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li D, Liu X, Lin L, et al: MicroRNA-99a
inhibits hepatocellular carcinoma growth and correlates with
prognosis of patients with hepatocellular carcinoma. J Biol Chem.
286:36677–36685. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Johnson DE and Williams LT: Structural and
functional diversity in the FGF receptor multigene family. Adv
Cancer Res. 60:1–41. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kwabi-Addo B, Ropiquet F, Giri D and
Ittmann M: Alternative splicing of fibroblast growth factor
receptors in human prostate cancer. Prostate. 46:163–172. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lafitte M, Moranvillier I, Garcia S, et
al: FGFR3 has tumor suppressor properties in cells with epithelial
phenotype. Mol Cancer. 12:832013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dorkin TJ, Robinson MC, Marsh C, Neal DE
and Leung HY: aFGF immunoreactivity in prostate cancer and its
co-localization with bFGF and FGF8. J Pathol. 189:564–569. 1999.
View Article : Google Scholar
|
|
28
|
Azab AK, Azab F, Quang P, et al: FGFR3 is
overexpressed waldenstrom macroglobulinemia and its inhibition by
Dovitinib induces apoptosis and overcomes stroma-induced
proliferation. Clin Cancer Res. 17:4389–4399. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wesche J, Haglund K and Haugsten EM:
Fibroblast growth factors and their receptors in cancer. BiochemJ.
437:199–213. 2011. View Article : Google Scholar
|
|
30
|
Ettelaie C, Fountain D, Collier ME, Elkeeb
AM, Xiao YP and Maraveyas A: Low molecular weight heparin
downregulates tissue factor expression and activity by modulating
growth factor receptor-mediated induction of nuclear factor-κB.
Biochim Biophys Acta. 1812:1591–1600. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lungu G, Covaleda L, Mendes O,
Martini-Stoica H and Stoica G: FGF-1-induced matrix
metalloproteinase-9 expression in breast cancer cells is mediated
by increased activities of NF-kappaB and activating protein-1. Mol
Carcinog. 47:424–435. 2008. View
Article : Google Scholar
|
|
32
|
Chaturvedi MM, Sung B, Yadav VR, Kannappan
R and Aggarwal BB: NF-κB addiction and its role in cancer: ‘one
size does not fit all’. Oncogene. 30:1615–1630. 2011. View Article : Google Scholar :
|
|
33
|
Perkins ND: The diverse and complex roles
of NF-κB subunits in cancer. Nat Rev Cancer. 12:121–132.
2012.PubMed/NCBI
|
|
34
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tomlinson DC, Hurst CD and Knowles MA:
Knockdown by shRNA identifies S249C mutant FGFR3 as a potential
therapeutic target in bladder cancer. Oncogene. 26:5889–5899. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hernández S, de Muga S, Agell L, et al:
FGFR3 mutations in prostate cancer: association with low-grade
tumors. Mod Pathol. 22:848–856. 2009.PubMed/NCBI
|
|
37
|
Hernández S, López-Knowles E, Lloreta J,
et al: Prospective study of FGFR3 mutations as a prognostic factor
in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol.
24:3664–3671. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gowardhan B, Douglas DA, Mathers ME, McKie
AB, McCracken SR, Robson CN and Leung HY: Evaluation of the
fibroblast growth factor system as a potential target for therapy
in human prostate cancer. Br J Cancer. 92:320–327. 2005.PubMed/NCBI
|
